Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)
Authors:
Open Access
- 4 May 2017
- journal article
- video audio-media
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 123,p. e55820
Abstract
Tumor Treating Fields (TTFields) are an effective treatment modality delivered via the continuous, noninvasive application of low-intensity (1-3 V/cm), alternating electric fields in the frequency range of several hundred kHz. The study of TTFields in tissue culture is carried out using the TTFields in vitro application system, which allows for the application of electric fields of varying frequencies and intensities to ceramic Petri dishes with a high dielectric constant (Ɛ > 5,000). Cancerous cell lines plated on coverslips at the bottom of the ceramic Petri dishes are subjected to TTFields delivered in two orthogonal directions at various frequencies to facilitate treatment outcome tests, such as cell counts and clonogenic assays. The results presented in this report demonstrate that the optimal frequency of the TTFields with respect to both cell counts and clonogenic assays is 200 kHz for both ovarian and glioma cells.Keywords
This publication has 20 references indexed in Scilit:
- Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivoInternational Journal of Cancer, 2016
- Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiationOncotarget, 2016
- Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesisOncotarget, 2016
- Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic ExitPLOS ONE, 2015
- Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF‐100A and TCCC after temozolomide and bevacizumab failure: a preliminary observationCancer Medicine, 2015
- Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A™ System Versus Best Physician’s Choice ChemotherapySeminars in Oncology, 2014
- A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancerLung Cancer, 2013
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modalityEuropean Journal of Cancer, 2012
- Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)BMC Medical Physics, 2009
- Disruption of Cancer Cell Replication by Alternating Electric FieldsCancer Research, 2004